Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

被引:77
作者
Lafuente-Lafuente, Carmelo [1 ]
Longas-Tejero, Miguel Angel [3 ]
Bergmann, Jean-Francois [2 ]
Belmin, Joel [4 ]
机构
[1] Univ Paris 06, Grp Hosp Pitie Salpetriere Charles Foix, AP HP, Serv Geriatrie Orientat Cardiol & Neurol, F-94205 Ivry, Ile De France, France
[2] Univ Paris 07, Hop Lariboisiere, AP HP, Serv Med Interne A, Paris, France
[3] Hosp Univ Principe Asturias, Serv Cardiol, Madrid, Spain
[4] Univ Paris 06, Triade Serv Hosp Univ Gerontol, Paris, France
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2012年 / 05期
关键词
Electric Countershock; Anti-Arrhythmia Agents [therapeutic use; Atrial Fibrillation [mortality; prevention & control; therapy; Randomized Controlled Trials as Topic; Recurrence [prevention & control; Humans; LOW-DOSE AMIODARONE; LONG-TERM EFFICACY; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PLACEBO-CONTROLLED TRIAL; CONGESTIVE-HEART-FAILURE; QUALITY-OF-LIFE; DOUBLE-BLIND; FLECAINIDE ACETATE; FOLLOW-UP; ELECTRICAL CARDIOVERSION;
D O I
10.1002/14651858.CD005049.pub3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Atrial fibrillation (AF) is the most frequent sustained arrhythmia. AF recurs frequently after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent recurrence, but the effect of these drugs on mortality and other clinical outcomes is unclear. Objectives To determine, in patients who recovered sinus rhythm after AF, the effect of long-term treatment with antiarrhythmic drugs on death, stroke and embolism, adverse effects, pro-arrhythmia, and recurrence of AF. Search methods We updated the searches of CENTRAL on The Cochrane Libary (Issue 1 of 4, 2010), MEDLINE (1950 to February 2010) and EMBASE (1966 to February 2010). The reference lists of retrieved articles, recent reviews and meta-analyses were checked. Selection criteria Two independent reviewers selected randomised controlled trials comparing any antiarrhythmic with a control (no treatment, placebo or drugs for rate control) or with another antiarrhythmic, in adults who had AF and in whom sinus rhythm was restored. Post-operative AF was excluded. Data collection and analysis Two reviewers independently assessed quality and extracted data. Studies were pooled, if appropriate, using Peto odds ratio (OR). All results were calculated at one year of follow-up. Main results In this update, 11 new studies met inclusion criteria, making a total of 56 included studies, comprising 20,771 patients. Compared with controls, class IA drugs quinidine and disopyramide (OR 2.39, 95% confidence interval (95%CI) 1.03 to 5.59, number needed to harm (NNH) 109, 95%CI 34 to 4985) and sotalol (OR 2.47, 95%CI 1.2 to 5.05, NNH 166, 95%CI 61 to 1159) were associated with increased all-cause mortality. Other antiarrhythmics did not seem to modify mortality. Several class IA (disopyramide, quinidine), IC (flecainide, propafenone) and III (amiodarone, dofetilide, dronedarone, sotalol) drugs significantly reduced recurrence of AF (OR 0.19 to 0.70, number needed to treat (NNT) 3 to 16). Beta-blockers (metoprolol) also reduced significantly AF recurrence (OR 0.62, 95% CI 0.44 to 0.88, NNT 9). All analysed drugs increased withdrawals due to adverse affects and all but amiodarone, dronedarone and propafenone increased pro-arrhythmia. We could not analyse other outcomes because few original studies reported them. Authors' conclusions Several class IA, IC and III drugs, as well as class II (beta-blockers), are moderately effective in maintaining sinus rhythm after conversion of atrial fibrillation. However, they increase adverse events, including pro-arrhythmia, and some of them (disopyramide, quinidine and sotalol) may increase mortality. Possible benefits on clinically relevant outcomes (stroke, embolisms, heart failure) remain to be established.
引用
收藏
页数:163
相关论文
共 211 条
[31]   PROPAFENON AND LIDOFLAZINE IN CHRONIC ATRIAL-FIBRILLATION AND FLUTTER [J].
BECK, OA ;
LEHMANN, HU ;
HOCHREIN, H .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1978, 103 (26) :1068-1072
[32]   Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation [J].
Bellandi, F ;
Simonetti, I ;
Leoncini, M ;
Frascarelli, F ;
Giovannini, T ;
Maioli, M ;
Dabizzi, RP .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (06) :640-645
[33]  
Bellandi F, 1996, G Ital Cardiol, V26, P379
[34]   PROPAFENONE AND SOTALOL IN THE PREVENTION OF PAROXYSMAL ATRIAL-FIBRILLATION - LONG-TERM SAFETY AND EFFICACY STUDY [J].
BELLANDI, F ;
DABIZZI, RP ;
NICCOLI, L ;
CANTINI, F .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (11) :1154-1168
[35]   Maintenance of sinus rhythm with oral d,I-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter [J].
Benditt, DG ;
Williams, JH ;
Jin, J ;
Deering, TF ;
Zucker, R ;
Browne, K ;
Chang-Sing, P ;
Singh, BN .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (03) :270-277
[36]   Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[37]   EFFICACY AND SAFETY OF FLECAINIDE ACETATE FOR ATRIAL TACHYCARDIA OR FIBRILLATION [J].
BERNS, E ;
RINKENBERGER, RL ;
JEANG, MK ;
DOUGHERTY, AH ;
JENKINS, M ;
NACCARELLI, GV .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (15) :1337-1341
[38]   AMIODARONE IN THE MANAGEMENT OF REFRACTORY ATRIAL-FIBRILLATION [J].
BLEVINS, RD ;
KERIN, NZ ;
BENADERET, D ;
FRUMIN, H ;
FAITEL, K ;
JARANDILLA, R ;
RUBENFIRE, M .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (08) :1401-1404
[39]  
BLOMSTROM P, 1984, ACTA MED SCAND, V216, P517
[40]  
Boissel J P, 1981, Eur Heart J, V2, P49